<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03874117</url>
  </required_header>
  <id_info>
    <org_study_id>SIT0003AGG</org_study_id>
    <secondary_id>R01DK118426</secondary_id>
    <nct_id>NCT03874117</nct_id>
  </id_info>
  <brief_title>Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function</brief_title>
  <official_title>Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palo Alto Veterans Institute for Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Palo Alto Veterans Institute for Research</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine the efficacy of twice weekly hemodialysis in patients with residual
      kidney function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hemodialysis patients who have residual kidney function will undergo two 4-week study (twice
      weekly versus thrice weekly hemodialysis). Blood, urine, and dialysate samples will be
      collected at the end of each study period to determine adequacy of treatment and to assess
      uremic solute levels. Participants will complete quality of life questionnaires and cognitive
      paper tests. Food records and medications may be monitored.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QOL: KDQOL36</measure>
    <time_frame>4 weeks</time_frame>
    <description>Kidney Disease Quality of Life: Health-related quality of life. Physical component and Mental Components are measured on a scale of 0 to 100, with higher scores being better.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solute Concentration</measure>
    <time_frame>4 weeks</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom</measure>
    <time_frame>4 weeks</time_frame>
    <description>Dialysis Symptom Index: measures symptom burden on a scale of 0 to 150, with higher scores being worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>4 weeks</time_frame>
    <description>Trail B Making Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition</measure>
    <time_frame>4 weeks</time_frame>
    <description>Digit Substitution Test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Kidney Failure, Chronic</condition>
  <arm_group>
    <arm_group_label>Twice weekly hemodialysis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will undergo hemodialysis twice per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thrice weekly hemodialysis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will undergo hemodialysis three times per week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Twice weekly hemodialysis</intervention_name>
    <description>Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.</description>
    <arm_group_label>Twice weekly hemodialysis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Thrice weekly hemodialysis</intervention_name>
    <description>Effect of hemodialysis prescriptions of twice weekly versus thrice weekly on quality of life will be evaluated. All hemodialysis will be prescribed to achieve adequate treatment based on current National Kidney Foundation guidelines.</description>
    <arm_group_label>Thrice weekly hemodialysis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable dialysis patients able to provide consent

        Exclusion Criteria:

          -  Use of antibiotics for last two months or expected antibiotic use

          -  Recent hospitalization or other event resulting in instability of food intake

          -  Residual kidney function &lt; 2.5 mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tammy Sirich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford/VA Palo Alto Health Care System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tammy Sirich, MD</last_name>
    <phone>650-493-5000</phone>
    <phone_ext>68321</phone_ext>
    <email>tsirich@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saniya Bonde, BS</last_name>
    <phone>650-493-5000</phone>
    <phone_ext>64599</phone_ext>
    <email>sbonde@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Medical Center</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Satellite HealthCare</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 10, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2019</study_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Palo Alto Veterans Institute for Research</investigator_affiliation>
    <investigator_full_name>Tammy Sirich</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

